PHAR300 Pharmacotherapy I Exam Prep – Real Practice Questions,
Answers & Detailed Rationales (Updated 2026) |
Pharmacokinetics & Pharmacodynamics, Drug Therapy Principles,
Cardiovascular & Respiratory Medications, Antibiotics & Antimicrobial
Therapy, Endocrine & Gastrointestinal Pharmacotherapy, Adverse Drug
Reactions, Medication Safety, Clinical Case Studies & Therapeutic
Decision-Making
Question 1: A 62-year-old male with hypertension and chronic kidney disease
(eGFR 35 mL/min/1.73m²) is being initiated on antihypertensive therapy. Which
agent is MOST appropriate as first-line treatment considering his renal
impairment?
A. Hydrochlorothiazide
B. Lisinopril
C. Amlodipine
D. Metoprolol succinate
CORRECT ANSWER: C. Amlodipine
Rationale: Amlodipine, a dihydropyridine calcium channel blocker, is preferred in
patients with chronic kidney disease because it does not require dose adjustment for
renal impairment and effectively lowers blood pressure without compromising renal
perfusion. ACE inhibitors like lisinopril are beneficial in CKD but require careful
monitoring of potassium and creatinine, and may not be ideal as monotherapy initiation
in advanced CKD without specific proteinuria indications. Thiazide diuretics lose
efficacy when eGFR falls below 30-40 mL/min. Beta-blockers are not first-line for
uncomplicated hypertension per current guidelines.
Question 2: Which statement BEST describes the mechanism of action of
empagliflozin in the management of type 2 diabetes mellitus?
A. It stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive
potassium channels
B. It inhibits dipeptidyl peptidase-4, thereby increasing incretin hormone levels
C. It blocks sodium-glucose cotransporter-2 in the proximal renal tubule, promoting
glucosuria
D. It activates peroxisome proliferator-activated receptor-gamma to improve insulin
sensitivity
CORRECT ANSWER: C. It blocks sodium-glucose cotransporter-2 in the proximal
renal tubule, promoting glucosuria
Rationale: Empagliflozin is an SGLT2 inhibitor that selectively inhibits sodium-glucose
cotransporter-2 in the proximal convoluted tubule of the nephron, reducing glucose
reabsorption and increasing urinary glucose excretion. This mechanism is insulin-
independent and also confers cardiovascular and renal benefits. Option A describes
,sulfonylureas, option B describes DPP-4 inhibitors, and option D describes
thiazolidinediones.
Question 3: A patient with newly diagnosed atrial fibrillation and a CHA₂DS₂-VASc
score of 3 requires anticoagulation. Which agent is preferred for stroke prevention
in this non-valvular atrial fibrillation patient without mechanical heart valves?
A. Warfarin with target INR 2.5
B. Apixaban 5 mg twice daily
C. Aspirin 325 mg daily
D. Clopidogrel 75 mg daily
CORRECT ANSWER: B. Apixaban 5 mg twice daily
Rationale: Direct oral anticoagulants (DOACs) like apixaban are preferred over warfarin
for stroke prevention in non-valvular atrial fibrillation due to comparable efficacy, lower
risk of intracranial hemorrhage, fewer drug-food interactions, and no requirement for
routine monitoring. Aspirin and clopidogrel are antiplatelet agents with inferior efficacy
for stroke prevention in AF and are not recommended as monotherapy for this
indication.
Question 4: Which adverse effect is MOST characteristic of long-term therapy with
high-potency first-generation antipsychotics such as haloperidol?
A. Weight gain and metabolic syndrome
B. Orthostatic hypotension and sedation
C. Tardive dyskinesia and extrapyramidal symptoms
D. Anticholinergic effects including dry mouth and constipation
CORRECT ANSWER: C. Tardive dyskinesia and extrapyramidal symptoms
Rationale: First-generation (typical) antipsychotics, particularly high-potency agents like
haloperidol, strongly block dopamine D₂ receptors in the nigrostriatal pathway, leading
to extrapyramidal symptoms (acute dystonia, parkinsonism, akathisia) and, with
chronic use, tardive dyskinesia. Metabolic effects are more prominent with second-
generation antipsychotics. Orthostatic hypotension and anticholinergic effects are
more common with low-potency typical antipsychotics like chlorpromazine.
Question 5: In the treatment of acute exacerbation of COPD, which medication
combination provides the MOST rapid bronchodilation?
A. Tiotropium plus salmeterol
B. Albuterol plus ipratropium via nebulizer
C. Fluticasone plus salmeterol dry powder inhaler
D. Theophylline extended-release tablets
CORRECT ANSWER: B. Albuterol plus ipratropium via nebulizer
Rationale: For acute COPD exacerbations, short-acting beta₂-agonists (albuterol)
combined with short-acting anticholinergics (ipratropium) via nebulizer provide rapid,
,synergistic bronchodilation. Tiotropium and salmeterol are long-acting agents used for
maintenance, not acute relief. Inhaled corticosteroid/LABA combinations are for
chronic management. Theophylline has a narrow therapeutic index, slow onset, and is
rarely used for acute exacerbations.
Question 6: A patient with rheumatoid arthritis is started on methotrexate. Which
supplementation is ESSENTIAL to reduce the risk of methotrexate-induced
toxicity?
A. Vitamin B₁₂
B. Folic acid
C. Calcium and vitamin D
D. Iron supplementation
CORRECT ANSWER: B. Folic acid
Rationale: Folic acid supplementation (typically 1 mg daily or 5 mg weekly) is mandatory
with methotrexate therapy to reduce the incidence of mucositis, gastrointestinal upset,
and hematologic toxicity without compromising therapeutic efficacy. Methotrexate
inhibits dihydrofolate reductase, depleting folate stores; supplementation mitigates this
effect. Vitamin B₁₂, calcium/vitamin D, and iron are not specifically indicated for
methotrexate toxicity prevention.
Question 7: Which antibiotic is the treatment of choice for community-acquired
pneumonia in a previously healthy adult with no recent antibiotic exposure and no
comorbidities?
A. Ciprofloxacin
B. Azithromycin
C. Vancomycin
D. Metronidazole
CORRECT ANSWER: B. Azithromycin
Rationale: For outpatient community-acquired pneumonia in healthy adults without
comorbidities or recent antibiotic use, guidelines recommend a macrolide
(azithromycin or clarithromycin) or doxycycline as first-line therapy to cover typical
pathogens like Streptococcus pneumoniae and atypical organisms. Fluoroquinolones
are reserved for patients with comorbidities or recent antibiotic exposure. Vancomycin
targets MRSA and is not first-line for CAP. Metronidazole covers anaerobes and is not
indicated for typical CAP.
Question 8: A patient with heart failure with reduced ejection fraction (HFrEF) is
already on lisinopril and metoprolol succinate. Which additional medication has
been shown to further reduce mortality and hospitalizations?
A. Furosemide
B. Digoxin
, C. Spironolactone
D. Hydralazine plus isosorbide dinitrate
CORRECT ANSWER: C. Spironolactone
Rationale: In HFrEF (NYHA class II-IV) with ejection fraction ≤35%, adding a
mineralocorticoid receptor antagonist (spironolactone or eplerenone) to ACE
inhibitor/ARB and beta-blocker therapy significantly reduces mortality and
hospitalizations, as demonstrated in the RALES trial. Furosemide provides symptom
relief but no mortality benefit. Digoxin reduces hospitalizations but not mortality.
Hydralazine/isosorbide is primarily indicated in African American patients or those
intolerant to ACEi/ARB.
Question 9: Which statement regarding the use of proton pump inhibitors (PPIs) is
MOST accurate?
A. PPIs should be taken with meals to maximize acid suppression
B. Long-term PPI use is associated with increased risk of Clostridioides difficile
infection
C. PPIs are more effective than H₂-receptor antagonists for immediate relief of
heartburn
D. PPIs require dose adjustment in patients with mild hepatic impairment
CORRECT ANSWER: B. Long-term PPI use is associated with increased risk of
Clostridioides difficile infection
Rationale: Chronic PPI use reduces gastric acidity, which may allow colonization and
overgrowth of pathogens like C. difficile, increasing infection risk. PPIs should be taken
30-60 minutes BEFORE meals for optimal activation of proton pumps. While PPIs
provide superior acid suppression compared to H₂RAs, they have a slower onset and
are not ideal for immediate relief. Most PPIs do not require dose adjustment in mild
hepatic impairment, though caution is advised in severe impairment.
Question 10: A patient with major depressive disorder has failed adequate trials of
two SSRIs. Which agent is MOST appropriate as a next-step pharmacotherapy
option?
A. Switch to another SSRI
B. Augment with buspirone
C. Switch to venlafaxine
D. Augment with lithium
CORRECT ANSWER: C. Switch to venlafaxine
Rationale: After failure of two adequate SSRI trials, guidelines suggest switching to an
antidepressant of a different class, such as an SNRI (venlafaxine, duloxetine).
Augmentation strategies (e.g., with lithium, atypical antipsychotics, or buspirone) are
typically considered after failure of two different-class monotherapies. Switching to
Answers & Detailed Rationales (Updated 2026) |
Pharmacokinetics & Pharmacodynamics, Drug Therapy Principles,
Cardiovascular & Respiratory Medications, Antibiotics & Antimicrobial
Therapy, Endocrine & Gastrointestinal Pharmacotherapy, Adverse Drug
Reactions, Medication Safety, Clinical Case Studies & Therapeutic
Decision-Making
Question 1: A 62-year-old male with hypertension and chronic kidney disease
(eGFR 35 mL/min/1.73m²) is being initiated on antihypertensive therapy. Which
agent is MOST appropriate as first-line treatment considering his renal
impairment?
A. Hydrochlorothiazide
B. Lisinopril
C. Amlodipine
D. Metoprolol succinate
CORRECT ANSWER: C. Amlodipine
Rationale: Amlodipine, a dihydropyridine calcium channel blocker, is preferred in
patients with chronic kidney disease because it does not require dose adjustment for
renal impairment and effectively lowers blood pressure without compromising renal
perfusion. ACE inhibitors like lisinopril are beneficial in CKD but require careful
monitoring of potassium and creatinine, and may not be ideal as monotherapy initiation
in advanced CKD without specific proteinuria indications. Thiazide diuretics lose
efficacy when eGFR falls below 30-40 mL/min. Beta-blockers are not first-line for
uncomplicated hypertension per current guidelines.
Question 2: Which statement BEST describes the mechanism of action of
empagliflozin in the management of type 2 diabetes mellitus?
A. It stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive
potassium channels
B. It inhibits dipeptidyl peptidase-4, thereby increasing incretin hormone levels
C. It blocks sodium-glucose cotransporter-2 in the proximal renal tubule, promoting
glucosuria
D. It activates peroxisome proliferator-activated receptor-gamma to improve insulin
sensitivity
CORRECT ANSWER: C. It blocks sodium-glucose cotransporter-2 in the proximal
renal tubule, promoting glucosuria
Rationale: Empagliflozin is an SGLT2 inhibitor that selectively inhibits sodium-glucose
cotransporter-2 in the proximal convoluted tubule of the nephron, reducing glucose
reabsorption and increasing urinary glucose excretion. This mechanism is insulin-
independent and also confers cardiovascular and renal benefits. Option A describes
,sulfonylureas, option B describes DPP-4 inhibitors, and option D describes
thiazolidinediones.
Question 3: A patient with newly diagnosed atrial fibrillation and a CHA₂DS₂-VASc
score of 3 requires anticoagulation. Which agent is preferred for stroke prevention
in this non-valvular atrial fibrillation patient without mechanical heart valves?
A. Warfarin with target INR 2.5
B. Apixaban 5 mg twice daily
C. Aspirin 325 mg daily
D. Clopidogrel 75 mg daily
CORRECT ANSWER: B. Apixaban 5 mg twice daily
Rationale: Direct oral anticoagulants (DOACs) like apixaban are preferred over warfarin
for stroke prevention in non-valvular atrial fibrillation due to comparable efficacy, lower
risk of intracranial hemorrhage, fewer drug-food interactions, and no requirement for
routine monitoring. Aspirin and clopidogrel are antiplatelet agents with inferior efficacy
for stroke prevention in AF and are not recommended as monotherapy for this
indication.
Question 4: Which adverse effect is MOST characteristic of long-term therapy with
high-potency first-generation antipsychotics such as haloperidol?
A. Weight gain and metabolic syndrome
B. Orthostatic hypotension and sedation
C. Tardive dyskinesia and extrapyramidal symptoms
D. Anticholinergic effects including dry mouth and constipation
CORRECT ANSWER: C. Tardive dyskinesia and extrapyramidal symptoms
Rationale: First-generation (typical) antipsychotics, particularly high-potency agents like
haloperidol, strongly block dopamine D₂ receptors in the nigrostriatal pathway, leading
to extrapyramidal symptoms (acute dystonia, parkinsonism, akathisia) and, with
chronic use, tardive dyskinesia. Metabolic effects are more prominent with second-
generation antipsychotics. Orthostatic hypotension and anticholinergic effects are
more common with low-potency typical antipsychotics like chlorpromazine.
Question 5: In the treatment of acute exacerbation of COPD, which medication
combination provides the MOST rapid bronchodilation?
A. Tiotropium plus salmeterol
B. Albuterol plus ipratropium via nebulizer
C. Fluticasone plus salmeterol dry powder inhaler
D. Theophylline extended-release tablets
CORRECT ANSWER: B. Albuterol plus ipratropium via nebulizer
Rationale: For acute COPD exacerbations, short-acting beta₂-agonists (albuterol)
combined with short-acting anticholinergics (ipratropium) via nebulizer provide rapid,
,synergistic bronchodilation. Tiotropium and salmeterol are long-acting agents used for
maintenance, not acute relief. Inhaled corticosteroid/LABA combinations are for
chronic management. Theophylline has a narrow therapeutic index, slow onset, and is
rarely used for acute exacerbations.
Question 6: A patient with rheumatoid arthritis is started on methotrexate. Which
supplementation is ESSENTIAL to reduce the risk of methotrexate-induced
toxicity?
A. Vitamin B₁₂
B. Folic acid
C. Calcium and vitamin D
D. Iron supplementation
CORRECT ANSWER: B. Folic acid
Rationale: Folic acid supplementation (typically 1 mg daily or 5 mg weekly) is mandatory
with methotrexate therapy to reduce the incidence of mucositis, gastrointestinal upset,
and hematologic toxicity without compromising therapeutic efficacy. Methotrexate
inhibits dihydrofolate reductase, depleting folate stores; supplementation mitigates this
effect. Vitamin B₁₂, calcium/vitamin D, and iron are not specifically indicated for
methotrexate toxicity prevention.
Question 7: Which antibiotic is the treatment of choice for community-acquired
pneumonia in a previously healthy adult with no recent antibiotic exposure and no
comorbidities?
A. Ciprofloxacin
B. Azithromycin
C. Vancomycin
D. Metronidazole
CORRECT ANSWER: B. Azithromycin
Rationale: For outpatient community-acquired pneumonia in healthy adults without
comorbidities or recent antibiotic use, guidelines recommend a macrolide
(azithromycin or clarithromycin) or doxycycline as first-line therapy to cover typical
pathogens like Streptococcus pneumoniae and atypical organisms. Fluoroquinolones
are reserved for patients with comorbidities or recent antibiotic exposure. Vancomycin
targets MRSA and is not first-line for CAP. Metronidazole covers anaerobes and is not
indicated for typical CAP.
Question 8: A patient with heart failure with reduced ejection fraction (HFrEF) is
already on lisinopril and metoprolol succinate. Which additional medication has
been shown to further reduce mortality and hospitalizations?
A. Furosemide
B. Digoxin
, C. Spironolactone
D. Hydralazine plus isosorbide dinitrate
CORRECT ANSWER: C. Spironolactone
Rationale: In HFrEF (NYHA class II-IV) with ejection fraction ≤35%, adding a
mineralocorticoid receptor antagonist (spironolactone or eplerenone) to ACE
inhibitor/ARB and beta-blocker therapy significantly reduces mortality and
hospitalizations, as demonstrated in the RALES trial. Furosemide provides symptom
relief but no mortality benefit. Digoxin reduces hospitalizations but not mortality.
Hydralazine/isosorbide is primarily indicated in African American patients or those
intolerant to ACEi/ARB.
Question 9: Which statement regarding the use of proton pump inhibitors (PPIs) is
MOST accurate?
A. PPIs should be taken with meals to maximize acid suppression
B. Long-term PPI use is associated with increased risk of Clostridioides difficile
infection
C. PPIs are more effective than H₂-receptor antagonists for immediate relief of
heartburn
D. PPIs require dose adjustment in patients with mild hepatic impairment
CORRECT ANSWER: B. Long-term PPI use is associated with increased risk of
Clostridioides difficile infection
Rationale: Chronic PPI use reduces gastric acidity, which may allow colonization and
overgrowth of pathogens like C. difficile, increasing infection risk. PPIs should be taken
30-60 minutes BEFORE meals for optimal activation of proton pumps. While PPIs
provide superior acid suppression compared to H₂RAs, they have a slower onset and
are not ideal for immediate relief. Most PPIs do not require dose adjustment in mild
hepatic impairment, though caution is advised in severe impairment.
Question 10: A patient with major depressive disorder has failed adequate trials of
two SSRIs. Which agent is MOST appropriate as a next-step pharmacotherapy
option?
A. Switch to another SSRI
B. Augment with buspirone
C. Switch to venlafaxine
D. Augment with lithium
CORRECT ANSWER: C. Switch to venlafaxine
Rationale: After failure of two adequate SSRI trials, guidelines suggest switching to an
antidepressant of a different class, such as an SNRI (venlafaxine, duloxetine).
Augmentation strategies (e.g., with lithium, atypical antipsychotics, or buspirone) are
typically considered after failure of two different-class monotherapies. Switching to
